Phenergan (Promethazine) 25 mg + Haloperidol 5 mg in CKD - Safety Assessment

Promethazine 25 mg in CKD

"Dose reduction usually not necessary; however, promethazine has a long half-life so monitor for excessive sedative effects in patients with renal impairment."

• No formal dose adjustment is required in renal impairment (StatPearls / NIH; Pediatric Surgical Associates renal dosing reference)
• Promethazine is primarily hepatically metabolised; renal excretion of unchanged drug is minimal
• The concern is its long half-life leading to sedative accumulation in CKD, particularly in severe impairment or ESRD
• The NHS East London Trust PGD explicitly lists "renal insufficiency" as a caution (not an absolute contraindication), recommending use with care

• Prolonged/excessive sedation
• Anticholinergic effects (urinary retention, dry mouth) - more pronounced in CKD
• Neuroleptic Malignant Syndrome (NMS) risk - a rare but serious concern, especially when combined with antipsychotics (Washington Manual of Medical Therapeutics)

Haloperidol 5 mg in CKD

"Less than 1% excreted unchanged in urine. Manufacturer advises caution in renal failure. Dosage: GFR 10-50 mL/min - dose as in normal renal function; GFR <10 mL/min - start with small doses and monitor."

"Since less than 3% of administered haloperidol is eliminated unchanged in the urine, impairment of renal function is not expected to affect its elimination. Therefore, dosage adjustment is not required in patients with renal impairment, but caution is advised."

• Haloperidol is considered one of the safer antipsychotics in renal disease due to its predominantly hepatic metabolism
• Current Psychiatry review: "Haloperidol is considered safe in renal disease because <1% of the medication is excreted unchanged through urine."
• Avoid depot preparations in renal impairment (Maudsley Guidelines)
• Caution in severe CKD/ESRD - start with lower doses and titrate slowly

Combination Use: Promethazine + Haloperidol in CKD

Practical Recommendations

1. Promethazine 25 mg - acceptable as a single dose for acute use (e.g., nausea, acute agitation adjunct); avoid repeated dosing without reassessment in moderate-severe CKD
2. Haloperidol 5 mg - acceptable in CKD; consider starting with 2.5 mg in severe CKD (GFR <10) and titrating up
3. Monitor: sedation level, BP, HR, ECG (QTc), electrolytes (K+, Mg2+), urinary output
4. Avoid depot haloperidol in renal impairment
5. Reassess indication before each repeat dose, especially in ESRD or dialysis patients

Bottom line: The combination of promethazine 25 mg + haloperidol 5 mg is not contraindicated in CKD and is commonly used clinically. However, CKD patients - especially those with severe impairment (GFR <30) - require closer monitoring for sedation, hypotension, QTc prolongation, and anticholinergic effects due to reduced drug clearance and altered pharmacokinetics.

Acute Agitation in a Hemodialysis (ESRD) Patient: Phenergan 25 mg + Haloperidol 5 mg

Key Pharmacokinetic Facts for Hemodialysis Patients

• There is no dose supplementation needed after HD sessions
• But also no safety rescue via dialysis if over-sedation or toxicity occurs - the drugs will stay in the system

Is the Combination Acceptable in This Scenario?

Dose Modifications for ESRD/HD

• Maudsley Guidelines: GFR <10 mL/min (ESRD) - start with small doses and titrate
• 5 mg is the standard adult dose for agitation - in ESRD, consider 2.5 mg IM as starting dose, especially if the patient is elderly, frail, or naive to antipsychotics
• Reassess response at 20-30 minutes before repeating
• If the patient has received haloperidol before and tolerated it, 5 mg is reasonable

• No dose adjustment required in ESRD per most guidelines (StatPearls, Pediatric Surgical Associates renal drug dosing)
• However: "Use with caution as it may produce excessive sedation in renal impairment" (PMC CKD psychiatry review)
• 25 mg is acceptable as a single dose - but given the additive sedation with haloperidol in an ESRD patient, consider 12.5-25 mg as a cautious starting point
• Do not repeat promethazine freely without reassessing sedation level

Critical Monitoring Points in This Patient

• ESRD patients commonly have electrolyte disturbances - hypokalemia, hypomagnesemia, hypocalcemia - all of which potentiate QTc prolongation
• Haloperidol prolongs QTc; promethazine has mild additive QT effects
• Get an ECG before administration if at all possible (or immediately after in an emergency)
• If QTc >500 ms or >60 ms above baseline, avoid or use with extreme caution
• Check K+, Mg2+ - correct deficiencies

• Neither drug is cleared by HD - sedation cannot be reversed by running an extra session
• Monitor consciousness level (GCS), respiratory rate, SpO2 continuously for at least 1-2 hours post-administration
• Have reversal ready if benzodiazepines are co-administered (flumazenil)

• Dialysis patients are often hemodynamically vulnerable - fluid shifted, autonomic dysfunction
• Promethazine (phenothiazine class) can cause significant hypotension in renal failure
• Monitor BP every 15 minutes for 1 hour post-dose

• Uremic encephalopathy makes ESRD patients more sensitive to EPS and dystonic reactions
• Promethazine itself has anticholinergic properties that partially offset haloperidol's EPS risk - this is one reason this combination is used - but anticholinergic load also increases with renal dysfunction

• Urinary retention is a real risk (especially in males with enlarged prostate)
• Monitor urine output post-dose

Timing Relative to Dialysis Session

• If the patient is currently on the dialysis machine: agitation during HD is a medical emergency - ensure the dialysis nurse is aware, consider whether to pause the session, and administer IM rather than IV where possible (IV haloperidol carries higher QTc risk)
• If the patient is between sessions: standard approach applies, but keep in mind that the drug effect will be longer-lasting since clearance is entirely hepatic

Alternative to Consider

• Haloperidol alone (2.5-5 mg IM) without promethazine reduces the anticholinergic and sedative burden
• Lorazepam 1-2 mg IM is an option for agitation (use with extreme caution in ESRD due to accumulation of active metabolites - propylene glycol vehicle in IV form is nephrotoxic)
• Avoid benzodiazepines if possible in ESRD - haloperidol alone is preferable

Summary

Clinical bottom line: Promethazine 25 mg + haloperidol 5 mg can be administered in an ESRD patient on hemodialysis for severe acute agitation. Neither drug is cleared by dialysis, so effects will be prolonged - use the lowest effective doses, get an ECG, correct electrolytes, and monitor closely. Start haloperidol at 2.5 mg if the patient is elderly or frail.

Can a Single Dose of Haloperidol 5 mg Cause QTc Prolongation?

What the Evidence Shows

1. Route Matters Enormously

"Sudden death, QT prolongation, and torsades de pointes, particularly when given intravenously or at dosages higher than those recommended."

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry

2. How Many Milliseconds Does It Actually Add?

• Oral haloperidol 2.5 mg/day in younger patients: mean QTc change of -1.2 ms (essentially no effect)
• Oral/IV haloperidol up to 30 mg/day: average QTc increase of only ~7 ms from baseline
• Low-dose haloperidol in hospitalised older adults (mean ~1-4 mg IV/day): no significant mean QTc prolongation in most studies; no TdP events observed
• When prolongation did occur in at-risk patients: mean increase of ~23 ms - below the dangerous threshold of >60 ms from baseline

3. When Does It Become Dangerous?

Specifically for Your ESRD/Hemodialysis Patient

• Electrolyte disturbances (hypokalemia, hypomagnesemia are common post/inter-dialysis)
• Possible uremic cardiomyopathy or LV hypertrophy
• Autonomic dysfunction from ESRD
• Promethazine being co-administered (mild additive QT effect)

Threshold Numbers to Know

Practical Recommendations for Your Patient

1. Get an ECG before or immediately after administration - check baseline QTc
2. Check K+ and Mg2+ - correct any deficiency before/alongside giving the drug (IV Mg2+ also treats TdP if it occurs)
3. Use IM, not IV route for acute agitation - lower peak levels, less QTc effect
4. If QTc >500 ms at baseline - avoid haloperidol; consider alternatives (midazolam 2-5 mg IM, noting its own risks in ESRD)
5. Monitor cardiac rhythm for at least 1 hour post-administration in this high-risk patient
6. Watch for symptoms of TdP: palpitations, dizziness, syncope - get ECG immediately if these occur

Bottom line: A single 5 mg IM haloperidol in a patient with normal QTc and no risk factors causes only a few milliseconds of QTc change - clinically insignificant. But in your ESRD dialysis patient with likely electrolyte disturbances and possible baseline QTc prolongation, even one dose carries meaningful risk. Check the ECG and electrolytes first.

IM Haloperidol 5 mg: QTc Risk Reassessment

IM vs IV - Why It Matters for QTc

• Slower absorption - peak levels reached in 20-40 minutes, not seconds
• Lower Cmax than IV equivalent dose
• First-pass metabolism avoided (like IV) but rate of rise is much slower
• No bolus effect on cardiac ion channels

What the Evidence Says for IM Specifically

• Multiple studies of IM haloperidol for acute agitation show no clinically significant mean QTc prolongation at doses of 5-10 mg
• The Frontiers in Psychiatry 2023 naturalistic study found haloperidol monotherapy (predominantly IM/oral) was not independently associated with QTc prolongation at typical clinical doses
• Roberts & Hedges Clinical Procedures in Emergency Medicine: "It is not standard to obtain an ECG prior to [IM haloperidol] use" - though caution is still advised in at-risk patients
• No TdP events have been reported in any published study of standard-dose IM haloperidol for acute agitation

Risk Summary for Your Specific Patient

What You Still Need to Do

1. Check K+ and Mg2+ - this is the most important step. Hypokalemia and hypomagnesemia independently prolong QTc and are extremely common in dialysis patients, especially between or just after sessions. Correct them if low.
2. Get an ECG - not mandatory for a standard patient receiving IM haloperidol, but strongly recommended here given the ESRD context. It takes 2 minutes and changes your management if QTc is already >500 ms.
3. Watch for symptoms - palpitations, dizziness, sudden syncope after administration should prompt an immediate ECG.
4. Avoid repeating the dose frequently - the QTc risk is cumulative with repeated dosing. A single 5 mg IM dose is low risk; three doses in 2 hours is a different conversation.

Bottom line: IM haloperidol 5 mg carries a much lower QTc risk than IV. In a standard patient it would be considered safe without ECG monitoring. In your ESRD patient, the main concern is not the route or dose itself - it is the underlying electrolyte status. Correct K+ and Mg2+, get a baseline ECG if feasible, and you have done everything reasonable to mitigate the risk.